Market Place
Sourcing Support
Rigel Announces Fast Track for R289 in Lower-Risk MDS
02 Dec 2024 //
PR NEWSWIRE
Rigel Reports Q3 2024 Financials & Business Update
07 Nov 2024 //
PR NEWSWIRE
Optime Care Expands Partnership With Rigel For Tavalisse Distribution
16 Oct 2024 //
GLOBENEWSWIRE
Rigel Announces Inducement Grants Under NASDAQ Rule
04 Oct 2024 //
PR NEWSWIRE
Rigel to Present at the 2024 Cantor Global Healthcare Conference
12 Sep 2024 //
PR NEWSWIRE
Rigel Inks $162.5M Oncology Deal With Kissei For Asian Markets
05 Sep 2024 //
BIOSPECTRUM ASIA
Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update
06 Aug 2024 //
PR NEWSWIRE
Rigel Announces Q2 2024 Financial Results And Business Update Call
30 Jul 2024 //
PR NEWSWIRE
Optime Care Enhances Partnership with Rigel for GAVRETO Patients
27 Jun 2024 //
BUSINESSWIRE
Rigel Announces Reverse Stock Split
25 Jun 2024 //
PR NEWSWIRE
Rigel Announces Five Presentations At EHA2024 Congress
14 Jun 2024 //
PR NEWSWIRE
Rigel Highlights Three Posters At ASCO 2024 Annual Meeting
03 Jun 2024 //
PR NEWSWIRE
Rigel to Present at the Jefferies Global Healthcare Conference
30 May 2024 //
PR NEWSWIRE
Rigel To Report Q1 2024 Results, Host Webcast
30 Apr 2024 //
PR NEWSWIRE
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
10 Apr 2024 //
PR NEWSWIRE
Rigel Announces Publication of Data on REZLIDHIA in Post-Venetoclax Patients
04 Apr 2024 //
PR NEWSWIRE
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as CMO
12 Mar 2024 //
PR NEWSWIRE
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results
05 Mar 2024 //
PR NEWSWIRE
Rigel to Report Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 //
PR NEWSWIRE
Rigel Pharmaceuticals Provides Business Update
08 Jan 2024 //
PR NEWSWIRE
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05 Jan 2024 //
PR NEWSWIRE
Rigel Announces Collaboration with CONNECT to Conduct Phase 2 of Olutasidenib
04 Jan 2024 //
PR NEWSWIRE
Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
PR NEWSWIRE
Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance
08 Dec 2023 //
PR NEWSWIRE
Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update
07 Nov 2023 //
PR NEWSWIRE
Rigel to Present at the Jefferies London Healthcare Conference
06 Nov 2023 //
PR NEWSWIRE
Rigel Announces Webcast to Report Third Quarter 2023 Financial Results
31 Oct 2023 //
PR NEWSWIRE
Rigel Announces Presentation at the Upcoming IDWeek 2023
11 Oct 2023 //
PR NEWSWIRE
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
06 Oct 2023 //
PR NEWSWIRE
Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update
01 Aug 2023 //
PR NEWSWIRE
Rigel Announces Conference to Report Second Quarter 2023 Financial Results
25 Jul 2023 //
PR NEWSWIRE
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05 Jul 2023 //
PR NEWSWIRE
Rigel Announces Presentation of Data from Analysis of REZLIDHIA
07 Jun 2023 //
PR NEWSWIRE
Rigel Announces Poster Presentation at the Upcoming 2023 Annual Meeting
01 Jun 2023 //
PR NEWSWIRE
Rigel to Present at the Jefferies 2023 Global Healthcare Conference
31 May 2023 //
PR NEWSWIRE
Rigel Announces Conference Call and Webcast to Report 1Q 2023 FYR
25 Apr 2023 //
PR NEWSWIRE
Rigel Pharma Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
06 Apr 2023 //
PR NEWSWIRE
Rigel Reports Fourth Quarter and Full Year 2022 Financial Results
07 Mar 2023 //
PR NEWSWIRE
Rigel to Report Fourth Quarter and Full Year 2022 Financial Results
28 Feb 2023 //
PR NEWSWIRE
Rigel Announces Publication of REZLIDHIA Phase 2 Results in Blood Advances
02 Feb 2023 //
PR NEWSWIRE
National Comprehensive Cancer Network Adds REZLIDHIA to Practice Guidelines
18 Jan 2023 //
PR NEWSWIRE
Rigel Pharmaceuticals Provides Business Update
09 Jan 2023 //
PR NEWSWIRE
Rigel Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S
22 Dec 2022 //
PRNEWSWIRE
Rigel Doses First Patient in Phase 1b Study of R289
15 Dec 2022 //
PRNEWSWIRE
Optime, Specialty Pharmacy Management Organization to Partner with Rigel Pharma
13 Dec 2022 //
BUSINESSWIRE
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
09 Dec 2022 //
PRNEWSWIRE
Rigel wins US approval of rival drug to Servier leukemia treatment
03 Dec 2022 //
BIOPHARMADIVE
FDA approves Rezlidhia™ for leukaemia
02 Dec 2022 //
EUROPEANPHARMACEUTICALREVIEW
U.S. FDA approves Rigel Pharma`s treatment for a type of leukemia
02 Dec 2022 //
REUTERS
Rigel Announces Five Presentations at the Upcoming 64th ASH Meeting
03 Nov 2022 //
PRNEWSWIRE
Rigel Announces Top-line Results from FOCUS Phase 3 Clinical Trial
01 Nov 2022 //
PRNEWSWIRE
Rigel Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback
10 Oct 2022 //
PRNEWSWIRE
Rigel and Forma enter licence deal for acute myeloid leukaemia therapy
03 Aug 2022 //
PHARMACEUTICAL-TECHNOLOGY
Rigel bets $230M on Forma`s leukemia drug
02 Aug 2022 //
FIERCEBIOTECH
Rigel and Forma Announce Licensing Agreement for Olutasidenib in r/r AML
02 Aug 2022 //
PRNEWSWIRE
Rigel Announces Conference Call to Report Q2 2022 Financial Results
26 Jul 2022 //
PRNEWSWIRE
Rigel dives after Tavalisse fails Phase III trial in haemolytic anaemia
08 Jun 2022 //
FIRSTWORDPHARMA
Rigel Announces Top-line Results from FORWARD PIII Trial of Fostamatinib
08 Jun 2022 //
PRNEWSWIRE
Rigel Reports First Quarter 2022 Financial Results and Provides Business Update
03 May 2022 //
PRNEWSWIRE
Rigel Pharma Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
08 Apr 2022 //
PRNEWSWIRE
